Rebecca Abraham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rebecca Abraham has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Sam Abraham
Centre for Biosecurity and One Health, Harry Butler Institute, Murdoch University, Perth, WA 6150, Australia
11 shared publications - Darren J. Trott
Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, Australia
3 shared publications David Jordan
Centre for Biosecurity and One Health, Harry Butler Institute, Murdoch University , 90 South Street, Murdoch, Western Australia 6150
3 shared publications- Stephen W. Page
Neoculi Pty Ltd., Burwood, VIC 3125, Australia
3 shared publications - Adam McCluskey
Chemistry, School of Environmental and Life Science, The University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia
2 shared publications - Ashiqur Rahman
School of Veterinary Medicine, Murdoch University, Perth, WA 6150, Australia
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (7)
High-resolution characterization of the temporal and spatial distribution of antimicrobial resistance in Escherichia coli from pigs
Objectives: Livestock are recognized reservoirs of antimicrobial resistance (AMR). However, current surveillance often overlooks key ecological aspects such as spatial–temporal patterns and quantification of shedding levels of resistant bacteria. In particular, early detection of low-level shedding of resistance to critically important antimicrobials (CIAs), including extended-spectrum cephalosporins (ESCs) and fluoroquinolones (FQs), remains limited. Using commensal Escherichia coli as an indicator, we applied a high-throughput Robotic Antimicrobial Susceptibility Platform (RASP) to assess phenotypic resistance in isolates from 900 samples collected across 10 pig herds over 3 years. Methods: Quantitative assessments of antimicrobial resistance (cfu/g) were performed using selective agars containing antimicrobials, with plating and data capture (colony counting) automated on the RASP. Broth microdilution and whole-genome sequencing were performed on CIA-R E. coli using RASP. Results: Persistent resistance to ampicillin and tetracycline (∼5.8 log10 cfu/g) showed minimal variation between herds and years. Gentamicin resistance declined significantly (−0.23 log10 cfu/g/year, P < 0.0001), while ESC resistance rose significantly (0.16 log10 cfu/g/year, P = 0.015), although some herds showed no ESC shedding. Ciprofloxacin resistance was detected in 58% of samples but generally at lower levels (∼2.1 log10 cfu/g) with herd-level variability. Genomic analysis identified FQ-resistant sequence types ST744 and ST167 with global phylogenetic links, and ESC resistance was associated with blaCTX-M-1 on IncI1 plasmids. Conclusions: These findings reveal the ecological complexity of AMR in livestock and highlight limitations of standard surveillance in detecting rare resistances. Our study demonstrates how high-throughput robotics integrated with robust field design can enhance AMR monitoring and inform One Health strategies for mitigation.
- 3 June 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (7)
Open AccessHigh-resolution characterization of the temporal and spatial distribution of antimicrobial resistance in Escherichia coli from pigs
Objectives: Livestock are recognized reservoirs of antimicrobial resistance (AMR). However, current surveillance often overlooks key ecological aspects such as spatial–temporal patterns and quantification of shedding levels of resistant bacteria. In particular, early detection of low-level shedding of resistance to critically important antimicrobials (CIAs), including extended-spectrum cephalosporins (ESCs) and fluoroquinolones (FQs), remains limited. Using commensal Escherichia coli as an indicator, we applied a high-throughput Robotic Antimicrobial Susceptibility Platform (RASP) to assess phenotypic resistance in isolates from 900 samples collected across 10 pig herds over 3 years. Methods: Quantitative assessments of antimicrobial resistance (cfu/g) were performed using selective agars containing antimicrobials, with plating and data capture (colony counting) automated on the RASP. Broth microdilution and whole-genome sequencing were performed on CIA-R E. coli using RASP. Results: Persistent resistance to ampicillin and tetracycline (∼5.8 log10 cfu/g) showed minimal variation between herds and years. Gentamicin resistance declined significantly (−0.23 log10 cfu/g/year, P < 0.0001), while ESC resistance rose significantly (0.16 log10 cfu/g/year, P = 0.015), although some herds showed no ESC shedding. Ciprofloxacin resistance was detected in 58% of samples but generally at lower levels (∼2.1 log10 cfu/g) with herd-level variability. Genomic analysis identified FQ-resistant sequence types ST744 and ST167 with global phylogenetic links, and ESC resistance was associated with blaCTX-M-1 on IncI1 plasmids. Conclusions: These findings reveal the ecological complexity of AMR in livestock and highlight limitations of standard surveillance in detecting rare resistances. Our study demonstrates how high-throughput robotics integrated with robust field design can enhance AMR monitoring and inform One Health strategies for mitigation.
- Open Access
Current Challenges and Potential Strategies to Enhance Efficacy of Oral Phage Therapy in Food Animals: A Systematic Review with Quantitative Analysis
Phage therapy has enormous potential in combating bacterial resistance in food animals. However, its application via the oral route remains limited due to challenges associated with the gastrointestinal tract (GIT) environment and a lack of rigorous clinical trial evidence. Therefore, we systematically searched in Google Scholar, PubMed, Scopus, and Web of Science databases following PRISMA guidelines and finally identified 111 articles on oral phage therapy in food animals from where we summarized the key physiological and chemical factors of the gut environment hindering the effectiveness of oral phage therapy (OPT), examined the methods used to evaluate phage stability in the GI environment, and highlighted potential strategies to mitigate these challenges. In addition, we performed quantitative analysis to visualize in vitro pH and thermal stability patterns of phages targeting bacteria isolated from food animals and variability in buffer and incubation period across stability studies. The GIT consists of several anatomically and functionally distinct segments, where complex interactions occur among digestive enzymes, gastric acids, electrolytes, commensal microbiota, and mucosal immune components. The acidic pH of the stomach is a major barrier to successful oral phage delivery. According to our analysis of pH stability testing data from the reviewed studies, most phages targeting antimicrobial-resistant bacteria in food animals remained stable at pH 5–9 and inactivated under highly acidic (pH ≤ 2) or highly alkaline (pH ≥ 11) conditions. In addition, phages are susceptible to high temperatures (above 60 °C), digestive enzymes (e.g., pepsin, trypsin, lipases), bile salts, and host immune responses. Several in vitro laboratory techniques are available to assess phage stability under simulated GI conditions, but variations occur in the assessment protocols. Microencapsulation using alginate and chitosan has been used to protect phages from the adverse GI environment. Additionally, enteric-coated capsules, antacids, co-encapsulation with acid-neutralizing agents, consumption of alkaline water, and daily phage administration are suggested to improve phage survival and efficacy. For the successful clinical implementation of OPT in food animals, future research should focus on elucidating the molecular and physicochemical determinants of phage stability, understanding the humoral immune response to OPT, standardizing laboratory protocol for assessing phage viability, improving the scalability of encapsulation methods, and exploring other potential delivery techniques.
Open AccessCurrent Challenges and Potential Strategies to Enhance Efficacy of Oral Phage Therapy in Food Animals: A Systematic Review with Quantitative Analysis
Phage therapy has enormous potential in combating bacterial resistance in food animals. However, its application via the oral route remains limited due to challenges associated with the gastrointestinal tract (GIT) environment and a lack of rigorous clinical trial evidence. Therefore, we systematically searched in Google Scholar, PubMed, Scopus, and Web of Science databases following PRISMA guidelines and finally identified 111 articles on oral phage therapy in food animals from where we summarized the key physiological and chemical factors of the gut environment hindering the effectiveness of oral phage therapy (OPT), examined the methods used to evaluate phage stability in the GI environment, and highlighted potential strategies to mitigate these challenges. In addition, we performed quantitative analysis to visualize in vitro pH and thermal stability patterns of phages targeting bacteria isolated from food animals and variability in buffer and incubation period across stability studies. The GIT consists of several anatomically and functionally distinct segments, where complex interactions occur among digestive enzymes, gastric acids, electrolytes, commensal microbiota, and mucosal immune components. The acidic pH of the stomach is a major barrier to successful oral phage delivery. According to our analysis of pH stability testing data from the reviewed studies, most phages targeting antimicrobial-resistant bacteria in food animals remained stable at pH 5–9 and inactivated under highly acidic (pH ≤ 2) or highly alkaline (pH ≥ 11) conditions. In addition, phages are susceptible to high temperatures (above 60 °C), digestive enzymes (e.g., pepsin, trypsin, lipases), bile salts, and host immune responses. Several in vitro laboratory techniques are available to assess phage stability under simulated GI conditions, but variations occur in the assessment protocols. Microencapsulation using alginate and chitosan has been used to protect phages from the adverse GI environment. Additionally, enteric-coated capsules, antacids, co-encapsulation with acid-neutralizing agents, consumption of alkaline water, and daily phage administration are suggested to improve phage survival and efficacy. For the successful clinical implementation of OPT in food animals, future research should focus on elucidating the molecular and physicochemical determinants of phage stability, understanding the humoral immune response to OPT, standardizing laboratory protocol for assessing phage viability, improving the scalability of encapsulation methods, and exploring other potential delivery techniques.
- Open Access
- 10 March 2026
- Published by Elsevier in Veterinary Microbiology
- Vol. 316, 110988
Application of bacteriophages to control bacterial infections of food animals in the era of antimicrobial resistance: An overview
- 10 March 2026
- Published by Elsevier in Veterinary Microbiology
- Vol. 316, 110988
Open AccessApplication of bacteriophages to control bacterial infections of food animals in the era of antimicrobial resistance: An overview
- Open Access
- 28 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Antimicrobial resistance and genomic characteristics of Campylobacter spp. From Australian meat chickens with A follow up investigation
The increasing resistance of bacteria to antimicrobials is a major threat to public health. This study investigates the prevalence of antimicrobial resistance, both phenotypic and genotypic, among Campylobacter isolates from Australian meat chickens in 2022, as a follow up to investigate trends since the last national surveillance undertaken in 2016. Isolates (n = 186) were obtained at slaughter from 200 pooled cecal samples taken from 1,000 meat chickens. The majority of C. jejuni (68.7%) and C. coli (88.9%) isolates were susceptible to all the antibiotics that were tested, and no multi-drug resistance was found. Resistance to ciprofloxacin (fluoroquinolone) was detected in 24.4% of the C. jejuni and 3.2% of the C. coli isolates. Whole genome sequencing revealed a diverse range of sequence types (STs). These included 32 previously reported STs for C. jejuni and 13 for C. coli, as well as four and seven previously undescribed STs for each species, respectively. The STs containing fluoroquinolone-resistant isolates were ST2083, ST10130, ST2895, ST7323, ST2398, and ST1078 for C. jejuni, and ST860 and ST894 for C. coli. Although fluoroquinolones are not used in animal production in Australia, resistance amongst C. jejuni isolates was high (24.4%). This finding emphasizes the need for enhanced surveillance and regular sampling along the food chain to understand the source of the isolates and to mitigate risks of antimicrobial resistance to protect public health.
- 28 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessAntimicrobial resistance and genomic characteristics of Campylobacter spp. From Australian meat chickens with A follow up investigation
The increasing resistance of bacteria to antimicrobials is a major threat to public health. This study investigates the prevalence of antimicrobial resistance, both phenotypic and genotypic, among Campylobacter isolates from Australian meat chickens in 2022, as a follow up to investigate trends since the last national surveillance undertaken in 2016. Isolates (n = 186) were obtained at slaughter from 200 pooled cecal samples taken from 1,000 meat chickens. The majority of C. jejuni (68.7%) and C. coli (88.9%) isolates were susceptible to all the antibiotics that were tested, and no multi-drug resistance was found. Resistance to ciprofloxacin (fluoroquinolone) was detected in 24.4% of the C. jejuni and 3.2% of the C. coli isolates. Whole genome sequencing revealed a diverse range of sequence types (STs). These included 32 previously reported STs for C. jejuni and 13 for C. coli, as well as four and seven previously undescribed STs for each species, respectively. The STs containing fluoroquinolone-resistant isolates were ST2083, ST10130, ST2895, ST7323, ST2398, and ST1078 for C. jejuni, and ST860 and ST894 for C. coli. Although fluoroquinolones are not used in animal production in Australia, resistance amongst C. jejuni isolates was high (24.4%). This finding emphasizes the need for enhanced surveillance and regular sampling along the food chain to understand the source of the isolates and to mitigate risks of antimicrobial resistance to protect public health.
- Open Access
- 23 May 2024
- Published by CSIRO Publishing in Microbiology Australia
- Vol. 45 (2) , 59-62
Antimicrobial resistance in production animals
There is growing recognition of the significant role food production animals play in the dissemination of antimicrobial-resistant bacteria. This issue is particularly relevant in the realm of food production, where the administration of antibiotics of importance to human health to animals can foster the emergence of resistant bacterial strains that may be transmitted to humans through the food supply chain. Further, resistance can develop to antibiotics of importance for animal health which can create health and productivity issues. Cross-sectional surveys of Australian food animal production systems have revealed that very low levels of antimicrobial resistance (AMR) are present in key bacterial species. Expansion of AMR surveillance in food production systems is, however, needed to improve the detection sensitivity of emerging resistances of importance to human and animal health. Scalable high throughput technologies, such as the robotic antimicrobial susceptibility platform (RASP), represents a step-fold change in the capacity to accurately detect AMR. Enhanced surveillance along with improved biosecurity, industry engagement and antimicrobial stewardship will contribute to maintaining low levels of AMR in Australia’s food production systems.
- 23 May 2024
- Published by CSIRO Publishing in Microbiology Australia
- Vol. 45 (2) , 59-62
Open AccessAntimicrobial resistance in production animals
There is growing recognition of the significant role food production animals play in the dissemination of antimicrobial-resistant bacteria. This issue is particularly relevant in the realm of food production, where the administration of antibiotics of importance to human health to animals can foster the emergence of resistant bacterial strains that may be transmitted to humans through the food supply chain. Further, resistance can develop to antibiotics of importance for animal health which can create health and productivity issues. Cross-sectional surveys of Australian food animal production systems have revealed that very low levels of antimicrobial resistance (AMR) are present in key bacterial species. Expansion of AMR surveillance in food production systems is, however, needed to improve the detection sensitivity of emerging resistances of importance to human and animal health. Scalable high throughput technologies, such as the robotic antimicrobial susceptibility platform (RASP), represents a step-fold change in the capacity to accurately detect AMR. Enhanced surveillance along with improved biosecurity, industry engagement and antimicrobial stewardship will contribute to maintaining low levels of AMR in Australia’s food production systems.
- Open Access
Antimicrobial Resistance, Genomic, and Public Health Insights into Enterococcus spp. from Australian Cattle
Enterococci are opportunistic, potentially life-threatening pathogens of humans that are difficult to manage due to antimicrobial resistance. Historically, enterococci entering the food-chain through livestock have been viewed as a likely source of antimicrobial resistance in humans. Australian human-derived clinical enterococci have a propensity to be resistant to multiple classes of antimicrobials including vancomycin. Recent Australian studies involving pigs and chicken have virtually excluded these species as reservoirs of infection for resistant enterococci in humans. However, the Australian bovine population has not been similarly assessed. This study investigates the antimicrobial resistance profiles of enterococci from Australian cattle and the phylogenetic relationship between E. faecium isolated from cattle and human sepsis cases. Minimum inhibitory concentration assays were performed for E. faecium (n=343), E. faecalis (n=92), and E. hirae (n=284) against a panel of 15 antimicrobials. The majority of isolates were sensitive to all tested antimicrobials. Erythromycin resistance was most prevalent for E. faecium isolates (18.7%), daptomycin for E. faecalis (12.1%) and tetracycline for E. hirae (13.3%). Phenotypically, 1 E. faecalis was resistant to vancomycin and 9 were resistant to linezolid ( E. faecium n=4, E. faecalis n=2, E. hirae n=3) but this was not confirmed with any know genotype. A subset of 67 E. faecium isolates selected for comparative phylogenetic analysis revealed that bovine isolates clustered with other livestock-derived and van-negative human isolates. In conclusion, there is a low prevalence of antimicrobial resistance amongst enterococci from Australian cattle which are unlikely to be precursor strains to vancomycin-resistant strains currently circulating in Australian hospitals. Importance: Enterococci resistant to critically important antimicrobials such as vancomycin and linezolid are difficult to manage in health care settings. Historically, there has been the belief that livestock can act as a reservoir of resistance for human infections. Previous studies in poultry and pork have demonstrated that isolates derived from these livestock are unlikely to be precursor strains for currently circulating vancomycin resistant- Enterococci causing infection in humans. To date, there has been no study looking at the genetic similarity of bovine derived Enterococci and the relationship to human pathogenic strains. In this study we performed phenotypic and genotypic characterization of bovine derived Enterococci along with comparative phylogenetic analysis with other livestock derived and human sepsis derived E. faecium isolates. We found that while non-vancomycin resistant strain sharing occurs between hosts, cattle are unlikely to be precursor strains for vancomycin resistant human E. faecium infections.
Open AccessAntimicrobial Resistance, Genomic, and Public Health Insights into Enterococcus spp. from Australian Cattle
Enterococci are opportunistic, potentially life-threatening pathogens of humans that are difficult to manage due to antimicrobial resistance. Historically, enterococci entering the food-chain through livestock have been viewed as a likely source of antimicrobial resistance in humans. Australian human-derived clinical enterococci have a propensity to be resistant to multiple classes of antimicrobials including vancomycin. Recent Australian studies involving pigs and chicken have virtually excluded these species as reservoirs of infection for resistant enterococci in humans. However, the Australian bovine population has not been similarly assessed. This study investigates the antimicrobial resistance profiles of enterococci from Australian cattle and the phylogenetic relationship between E. faecium isolated from cattle and human sepsis cases. Minimum inhibitory concentration assays were performed for E. faecium (n=343), E. faecalis (n=92), and E. hirae (n=284) against a panel of 15 antimicrobials. The majority of isolates were sensitive to all tested antimicrobials. Erythromycin resistance was most prevalent for E. faecium isolates (18.7%), daptomycin for E. faecalis (12.1%) and tetracycline for E. hirae (13.3%). Phenotypically, 1 E. faecalis was resistant to vancomycin and 9 were resistant to linezolid ( E. faecium n=4, E. faecalis n=2, E. hirae n=3) but this was not confirmed with any know genotype. A subset of 67 E. faecium isolates selected for comparative phylogenetic analysis revealed that bovine isolates clustered with other livestock-derived and van-negative human isolates. In conclusion, there is a low prevalence of antimicrobial resistance amongst enterococci from Australian cattle which are unlikely to be precursor strains to vancomycin-resistant strains currently circulating in Australian hospitals. Importance: Enterococci resistant to critically important antimicrobials such as vancomycin and linezolid are difficult to manage in health care settings. Historically, there has been the belief that livestock can act as a reservoir of resistance for human infections. Previous studies in poultry and pork have demonstrated that isolates derived from these livestock are unlikely to be precursor strains for currently circulating vancomycin resistant- Enterococci causing infection in humans. To date, there has been no study looking at the genetic similarity of bovine derived Enterococci and the relationship to human pathogenic strains. In this study we performed phenotypic and genotypic characterization of bovine derived Enterococci along with comparative phylogenetic analysis with other livestock derived and human sepsis derived E. faecium isolates. We found that while non-vancomycin resistant strain sharing occurs between hosts, cattle are unlikely to be precursor strains for vancomycin resistant human E. faecium infections.
- Open Access
- 29 September 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (21)
Antigiardial Activity of Novel Guanidine Compounds
From four focused compound libraries based on the known anticoccidial agent robenidine, 44 compounds total were synthesised and screened for antigiardial activity. All active compounds were counter‐screened for antibiotic and cytotoxic action. Of the analogues examined, 21 displayed IC5050bis{[4‐(trifluoromethoxy)phenyl]methylene}carbonimidic dihydrazide hydrochloride (30), 2,2′‐bis{[4‐(trifluoromethylsulfanyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (32), and 2,2′‐bis[(2‐bromo‐4,5‐dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (41) with IC50=0.2 μM. The maximal observed activity was a 5 h IC50 value of 0.2 μM for 41. The clinically used metronidazole was inactive at this timepoint at a concentration of 25 μM. Robenidine off‐target effects at bacteria and cell line toxicity were removed. Analogue 41 was well tolerated in mice treated orally (100 mg/kg). Following 5 h treatment with 41, no Giardia regrowth was noted after 48 h.
- 29 September 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (21)
Open AccessAntigiardial Activity of Novel Guanidine Compounds
From four focused compound libraries based on the known anticoccidial agent robenidine, 44 compounds total were synthesised and screened for antigiardial activity. All active compounds were counter‐screened for antibiotic and cytotoxic action. Of the analogues examined, 21 displayed IC5050bis{[4‐(trifluoromethoxy)phenyl]methylene}carbonimidic dihydrazide hydrochloride (30), 2,2′‐bis{[4‐(trifluoromethylsulfanyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (32), and 2,2′‐bis[(2‐bromo‐4,5‐dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (41) with IC50=0.2 μM. The maximal observed activity was a 5 h IC50 value of 0.2 μM for 41. The clinically used metronidazole was inactive at this timepoint at a concentration of 25 μM. Robenidine off‐target effects at bacteria and cell line toxicity were removed. Analogue 41 was well tolerated in mice treated orally (100 mg/kg). Following 5 h treatment with 41, no Giardia regrowth was noted after 48 h.
- Open Access
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1293
GS-2: A Novel Broad-Spectrum Agent for Environmental Microbial Control
The environmental control of microbial pathogens currently relies on compounds that do not exert long-lasting activity on surfaces, are impaired by soil, and contribute to the growing problem of antimicrobial resistance. This study presents the scientific development and characterization of GS-2, a novel, water-soluble ammonium carboxylate salt of capric acid and L-arginine that demonstrates activity against a range of bacteria (particularly Gram-negative bacteria), fungi, and viruses. In real-world surface testing, GS-2 was more effective than a benzalkonium chloride disinfectant at reducing the bacterial load on common touch-point surfaces in a high-traffic building (average 1.6 vs. 32.6 CFUs recovered from surfaces 90 min after application, respectively). Toxicology testing in rats confirmed GS-2 ingredients were rapidly cleared and posed no toxicities to humans or animals. To enhance the time-kill against Gram-positive bacteria, GS-2 was compounded at a specific ratio with a naturally occurring monoterpenoid, thymol, to produce a water-based antimicrobial solution. This GS-2 with thymol formulation could generate a bactericidal effect after five minutes of exposure and a viricidal effect after 10 min of exposure. Further testing of the GS-2 and thymol combination on glass slides demonstrated that the compound retained bactericidal activity for up to 60 days. Based on these results, GS-2 and GS-2 with thymol represent a novel antimicrobial solution that may have significant utility in the long-term reduction of environmental microbial pathogens in a variety of settings.
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1293
Open AccessGS-2: A Novel Broad-Spectrum Agent for Environmental Microbial Control
The environmental control of microbial pathogens currently relies on compounds that do not exert long-lasting activity on surfaces, are impaired by soil, and contribute to the growing problem of antimicrobial resistance. This study presents the scientific development and characterization of GS-2, a novel, water-soluble ammonium carboxylate salt of capric acid and L-arginine that demonstrates activity against a range of bacteria (particularly Gram-negative bacteria), fungi, and viruses. In real-world surface testing, GS-2 was more effective than a benzalkonium chloride disinfectant at reducing the bacterial load on common touch-point surfaces in a high-traffic building (average 1.6 vs. 32.6 CFUs recovered from surfaces 90 min after application, respectively). Toxicology testing in rats confirmed GS-2 ingredients were rapidly cleared and posed no toxicities to humans or animals. To enhance the time-kill against Gram-positive bacteria, GS-2 was compounded at a specific ratio with a naturally occurring monoterpenoid, thymol, to produce a water-based antimicrobial solution. This GS-2 with thymol formulation could generate a bactericidal effect after five minutes of exposure and a viricidal effect after 10 min of exposure. Further testing of the GS-2 and thymol combination on glass slides demonstrated that the compound retained bactericidal activity for up to 60 days. Based on these results, GS-2 and GS-2 with thymol represent a novel antimicrobial solution that may have significant utility in the long-term reduction of environmental microbial pathogens in a variety of settings.
- Open Access
- 1 August 2019
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 10, 38-44
Aminoguanidines: New leads for treatment of Giardia duodenalis infection
- 1 August 2019
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 10, 38-44
Open AccessAminoguanidines: New leads for treatment of Giardia duodenalis infection